Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNFWNASDAQ:CEROWNASDAQ:DRTSWNASDAQ:SXTPW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNFW180 Life Sciences$0.01+1.2%$0.01$0.00▼$0.04N/AN/A98,841 shs117,613 shsCEROWCERo Therapeutics$0.03+11.7%$0.02$0.00▼$0.06N/AN/A135,192 shs60,156 shsDRTSWAlpha Tau Medical$0.23-4.2%$0.23$0.09▼$0.50N/AN/A20,617 shs600 shsSXTPW60 Degrees Pharmaceuticals$0.05-1.2%$0.06$0.01▼$0.10N/AN/A16,889 shs8,676 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNFW180 Life Sciences+1.20%-4.55%+12.00%+1.20%-14.29%CEROWCERo Therapeutics+11.74%+15.23%+85.53%+92.81%+76.65%DRTSWAlpha Tau Medical-4.24%-4.24%-9.56%+2.73%-9.60%SXTPW60 Degrees Pharmaceuticals0.00%-0.59%+1.20%+110.83%-27.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACEROWCERo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNFW180 Life Sciences 0.00N/AN/AN/ACEROWCERo Therapeutics 0.00N/AN/AN/ADRTSWAlpha Tau Medical 0.00N/AN/AN/ASXTPW60 Degrees Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNFW180 Life SciencesN/AN/AN/AN/AN/AN/ACEROWCERo TherapeuticsN/AN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/AN/ASXTPW60 Degrees Pharmaceuticals$665.45KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ACEROWCERo TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/A0.00∞N/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNFW180 Life SciencesN/AN/AN/AN/AN/ACEROWCERo TherapeuticsN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNFW180 Life SciencesN/ACEROWCERo TherapeuticsN/ADRTSWAlpha Tau MedicalN/ASXTPW60 Degrees PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipATNFW180 Life SciencesN/ACEROWCERo TherapeuticsN/ADRTSWAlpha Tau MedicalN/ASXTPW60 Degrees PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNFW180 Life Sciences7N/AN/ANot OptionableCEROWCERo Therapeutics8N/AN/AN/ADRTSWAlpha Tau Medical80N/AN/ANot OptionableSXTPW60 Degrees Pharmaceuticals2N/AN/ANot OptionableCEROW, ATNFW, SXTPW, and DRTSW HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVJune 6, 2025 | usatoday.com60 Degrees Pharmaceuticals Introduces New 8-Count Bottle for ARAKODA® Malaria ProphylaxisJune 6, 2025 | nasdaq.com60 Degrees introduces eight-count bottle format for ARAKODAJune 4, 2025 | msn.com60 Degrees announces results from an insurance claims analysis on babesiosisJune 4, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Highlights Major Discrepancies in Babesiosis Diagnosis Estimates in U.S.April 24, 2025 | nasdaq.com60 Degrees Pharmaceuticals signs Patient License Agreement with YaleApril 8, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals Announces 2024 Annual ResultsMarch 28, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Inc trading halted, news pendingFebruary 21, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals files to sell 3.74M shares of common stock for holderFebruary 14, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals announces stock and warrant saleJanuary 29, 2025 | msn.comThe Market’s Eyeing 60 Degrees Pharmaceuticals (SXTP): Will the Surge Last?January 29, 2025 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCEROW, ATNFW, SXTPW, and DRTSW Company Descriptions180 Life Sciences NASDAQ:ATNFW$0.0084 +0.00 (+1.20%) As of 06/25/2025 03:22 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.CERo Therapeutics NASDAQ:CEROW$0.03 +0.00 (+11.74%) As of 06/25/2025 03:56 PM EasternCERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.Alpha Tau Medical NASDAQ:DRTSW$0.23 -0.01 (-4.24%) As of 06/25/2025 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.60 Degrees Pharmaceuticals NASDAQ:SXTPW$0.05 0.00 (-1.17%) As of 06/24/2025 01:27 PM Eastern60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
